Royalty Pharma RPRX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.44B+2.6% | $2.38B+1.2% | $2.35B+1.9% | $2.31B+1.8% | $2.26B0.0% | ||
| $441.29M-2.4% | $452M+12.4% | $402M+14.2% | $352M+577% | $52M+2,500% | ||
| $622.27M+8.5% | $573.48M+20.3% | $476.8M+15.0% | $414.79M+43.2% | $289.72M+22.4% | ||
| —— | —— | —— | —— | $0— | ||
| $852.15M+4.1% | $818.67M+0.2% | $817.19M+75.9% | $464.67M+27.9% | $363.45M-62.6% | ||
| $1.59B+1.9% | $1.56B+1.8% | $1.53B-16.7% | $1.84B-3.1% | $1.9B+47.0% | ||
| 65.1%-0.5pp | 65.6%+0.4pp | 65.2%-14.6pp | 79.8%-4.1pp | 83.9%+26.8pp | ||
| $336.13M+9.3% | $307.66M+10.2% | $279.25M+4.9% | $266.2M+8.0% | $246.54M+9.3% | ||
| $28.53M-15.1% | $33.59M-5.5% | $35.56M-23.0% | $46.16M-9.9% | $51.22M+8.2% | ||
| -$229.36M+2.1% | -$234.33M— | —— | —— | —— | ||
| $44.4M+52.6% | $29.09M-48.7% | $56.73M+10.8% | $51.19M+2.0% | $50.2M+69.5% | ||
| $1.36B+2.6% | $1.33B+1.7% | $1.3B-21.7% | $1.67B-5.9% | $1.77B+33.0% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $827.29M+7.2% | $771.95M+0.8% | $765.96M-25.0% | $1.02B-6.6% | $1.09B+27.3% | ||
| 33.9%+1.4pp | 32.5%-0.1pp | 32.6%-11.7pp | 44.3%-4.0pp | 48.3%+10.4pp | ||
| $1.91+6.7% | $1.79+1.7% | $1.76-23.5% | $2.30-6.5% | $2.46+28.1% | ||
| $1.91+6.7% | $1.79+1.7% | $1.76-23.8% | $2.31-6.5% | $2.47+28.0% | ||
| 2.2B-0.9% | 2.3B-1.3% | 2.3B-1.4% | 2.3B-1.5% | 2.4B-0.8% | ||
| 1.7B+0.1% | 1.7B-1.1% | 1.7B-0.9% | 1.8B-1.5% | 1.8B-0.7% | ||
| $89.6M-4.0% | $93.3M0.0% | $93.3M+0.8% | $92.54M— | $0— | ||
| —— | —— | —— | —— | —— | ||
| $42.46M-7.4% | $45.86M-37.0% | $72.79M-6.7% | $77.99M-25.9% | $105.21M-32.1% | ||
| —— | —— | —— | —— | —— | ||
| $28.53M-15.1% | $33.59M-5.5% | $35.56M-23.0% | $46.16M-9.9% | $51.22M+8.2% | ||
| $311M+12.6% | $276.29M+2.2% | $270.42M+23.2% | $219.42M0.0% | $219.42M+37.5% | ||
| —— | —— | —— | —— | —— | ||
| -$2.6B-60.8% | -$1.61B-26.9% | -$1.27B+15.6% | -$1.51B+27.8% | -$2.09B+22.1% | ||
| $2.61B+4.9% | $2.49B+3.5% | $2.41B0.0% | $2.41B-10.9% | $2.7B-2.5% | ||
| -$13.49M+6.0% | -$14.35M-71.5% | -$8.37M+0.9% | -$8.45M-833% | -$905K+40.8% | ||
| $568.7M-53.7% | $1.23B+2.3% | $1.2B+4.3% | $1.15B+22.5% | $938.43M+309% | ||
| $2.15B+26.6% | $1.7B+16.2% | $1.46B-13.7% | $1.69B-30.1% | $2.42B-3.4% | ||
| $111.19M+5.7% | $105.15M+1.7% | $103.4M-9.3% | $113.98M+107% | $54.94M+132% | ||
| $12.96M-38.9% | $21.23M-31.4% | $30.93M0.0% | $30.93M0.0% | $30.93M+56.3% | ||
| -$389.29M-22.1% | -$318.94M-106% | -$154.91M+60.7% | -$394.65M-1,917% | $21.72M-97.0% | ||
| $1.59B+1.9% | $1.56B+1.8% | $1.53B-16.7% | $1.84B-3.1% | $1.9B+47.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Royalty Pharma's revenue?
- Royalty Pharma (RPRX) generated $2.4B in revenue over the trailing twelve months, up 7.8% year over year.
- Is Royalty Pharma profitable?
- Royalty Pharma reported $827.3M in net income over the trailing twelve months, a 33.9% net margin.
- What is Royalty Pharma's earnings per share?
- Royalty Pharma's diluted EPS over the trailing twelve months is $1.91.
- Where does Royalty Pharma's income statement data come from?
- Every line is extracted from Royalty Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
